samedan logo

 
 
spacer
home > ebr > winter 2003 > microarrays in the real world
PUBLICATIONS
European Biopharmaceutical Review

Microarrays in the Real World

Since the first microarrays were developed in the early 1990s, the technology for producing and reading has progressed in parallel to the number of applications found for them. The process of using a microarray can be split into four distinct phases; printing, hybridisation, reading and analysis (see Figure 1). As the twin processes of reading the array and analysing the date mediates the quality of the overall experiment, it is essential to understand the issues encountered in these final stages. By referring to the specifics of a two-colour microarray experiment, this article deals with the various practical issues encountered in reading a real chip, many of which are due to relatively simple optical and mechanical effects. The second part of this series will deal with the analysis of the raw image data. Anticipating the issues encountered in the latter two stages leads to both better images and ultimately better results.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Julian White, CEO at genapta Ltd

Since completing a PhD in Laser Spectroscopy at Cambridge University, Julian has worked in a number of engineering roles, managing a range of new product designs and introductions over the last decade. For the last five years he has been developing optical sensors for the semiconductor and biotech industries. genapta was founded in 2001 in order to address the potential of transferring techniques widespread in the telecommunications sector to life sciences.

spacer
Julian White
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health and ActiGraph simplify clinical trial activity and sleep monitoring for patients, sites, and sponsors with their new integration

Philadelphia, PA – November 14, 2019: Signant Health, formerly CRF Health and Bracket, is proud to announce that it has integrated its industry leading eCOA platform TrialMax®, with ActiGraph’s CentrePoint system. The integration, which includes ActiGraph’s FDA 510(k) cleared sensors, helps simplify the process of collecting and monitoring real-world activity, mobility, and sleep outcomes data for patients and researchers.
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement